Pramipexole

Dopamine agonist for Parkinson's disease and restless legs syndrome

Pramipexole is a selective dopamine agonist with high affinity for dopamine D2 receptor families, particularly D3 receptors, and is one of the most important medications in the treatment of idiopathic Parkinson's syndrome and restless legs syndrome (RLS). Unlike levodopa, pramipexole stimulates dopamine receptors directly, without first needing to be converted to dopamine. In Germany, pramipexole is available under the original preparation Mirapex and numerous generics, both as a standard tablet for multiple daily intake and as a modified-release tablet for once-daily intake.

Dopaminergic degeneration in the striatum is the pathophysiological core of Parkinson's syndrome. Through direct stimulation of postsynaptic dopamine receptors, pramipexole can compensate for the relative dopamine deficiency and relieve both motor and non-motor symptoms. Pramipexole is used both as monotherapy in early stages and in combination with levodopa in advanced stages.

Mechanism of Action

Pramipexole is a full agonist at D2, D3, and D4 dopamine receptors, with the highest affinity for D3 receptors. These receptors belong to the D2 receptor family (Gi protein-coupled) and are localised in the striatum, the limbic system, and other areas of the brain.

Through direct activation of postsynaptic D2/D3 receptors in the striatum, pramipexole mimics the physiological effect of dopamine and thus compensates for the neuronal dopamine deficiency that arises in Parkinson's syndrome through the degeneration of dopaminergic neurons in the substantia nigra. This direct receptor agonism distinguishes pramipexole from levodopa, which must first be converted to dopamine.

The preferential effect on D3 receptors, which are particularly expressed in the limbic system, explains the positive effects on non-motor symptoms of Parkinson's syndrome such as depression and anxiety. D3 receptors in the limbic system are also relevant in the pathophysiology of RLS and the modulation of impulse control, which can explain both the therapeutic benefit and the side effects (impulse control disorders).

Pramipexole crosses the blood-brain barrier well and has a half-life of approximately 8 to 12 hours (standard formulation). The modified-release formulation achieves more even plasma levels over 24 hours.

Indications

• Idiopathic Parkinson's syndrome: Monotherapy in early stages; combination therapy with levodopa in advanced stages to reduce motor fluctuations (wearing-off phenomena)
• Restless legs syndrome (RLS): Moderate to severe idiopathic RLS in adults; pramipexole is considered first-line therapy for RLS requiring drug treatment
• Off-label applications: Bipolar depression (investigated in studies), treatment-resistant depression (adjunctive)

Dosage and Administration

Parkinson's syndrome (standard tablets): Starting dose 0.088 mg three times daily (corresponding to 0.264 mg/day as pramipexole dihydrochloride monohydrate); weekly increase by 0.088 mg per individual dose over 7 weeks to a maintenance dose of 0.5 to 1.1 mg three times daily. Maximum daily dose: 3.3 mg three times daily. Parkinson's syndrome (modified-release tablets): Once daily at a fixed time of day; starting dose 0.26 mg, increase weekly, max. 3.15 mg/day.

Restless legs syndrome: 0.088 mg once daily 2 to 3 hours before bedtime; increase after 4 to 7 days to 0.18 mg, if necessary further to max. 0.54 mg daily. No modified-release formulation approved for RLS.

Pramipexole can be taken with or without meals; if nausea occurs, taking with a meal is recommended. Do not split, crush, or chew modified-release tablets. In renal insufficiency (creatinine clearance below 50 ml/min), dosage must be adjusted, as pramipexole is predominantly renally eliminated. Dose reduction and discontinuation should always be done gradually.

Side Effects

Very common and common: Drowsiness and somnolence (especially at the start of therapy), dizziness, nausea (particularly initially), headache, dyskinesias (involuntary movements, more common in combination with levodopa), orthostatic hypotension (drop in blood pressure on standing), insomnia, nightmares, behavioural changes.

Impulse control disorders (important class side effect): Pathological gambling, hypersexuality, compulsive buying, binge eating, and other impulse control disorders can occur with dopamine agonists. The risk increases with higher doses and in younger patients. Patients and carers must be informed about these side effects; therapy adjustment or discontinuation of the active ingredient is necessary with relevant severity.

Sudden onset of sleep: Patients can fall asleep suddenly (sleep attacks), including while driving. Driving ability must be actively assessed.

Occasional to rare: Hallucinations (particularly in elderly Parkinson's patients), confusion, paranoia, augmentation in RLS (paradoxical worsening of RLS symptoms with long-term therapy), cardiac arrhythmias, peripheral oedema.

Interactions

Dopamine antagonists (neuroleptics, metoclopramide, domperidone): Antagonise the effect of pramipexole and can worsen Parkinson's symptoms. Neuroleptics should be avoided if possible in Parkinson's patients; if unavoidable, preferably quetiapine or clozapine (lower D2 blockade).

Cimetidine (H2 blocker): Inhibits renal tubular secretion of pramipexole and can increase its plasma levels by approximately 50 percent; dose adjustment of pramipexole may be necessary.

Other renal cation transporter substrates: Amantadine, digoxin, verapamil, quinidine can affect the renal excretion of pramipexole.

Alcohol: Enhances the sedating effect; consumption should be avoided during therapy.

Levodopa: Combination is often desired (synergism); increased risk of dyskinesias and hallucinations; levodopa dose must often be reduced with combination therapy.

Special Notes

Augmentation in RLS: With long-term RLS therapy, augmentation may occur: symptoms intensify, begin earlier in the day, or spread to other body parts. With augmentation, the dose should not be increased but a change of therapy should be considered.

Pregnancy and breastfeeding: Pramipexole is not recommended during pregnancy. Animal studies showed embryotoxicity. As pramipexole inhibits prolactin secretion, it can impair breastfeeding. If possible, a switch to levodopa during pregnancy should be made.

Cardiac diseases: Caution is required in patients with severe heart failure, as dopamine agonists can affect cardiac function. Regular cardiological monitoring is recommended with pre-existing cardiac conditions.

Renal function: As pramipexole is more than 90 percent renally excreted, dose adjustment is obligatory with impaired renal function. Regular monitoring of renal function (creatinine clearance) is recommended.

Frequently Asked Questions

How does pramipexole differ from levodopa in Parkinson's?

Levodopa is a precursor to dopamine and is converted to dopamine in the brain; it is very effective but frequently leads to motor fluctuations and dyskinesias in the long term. Pramipexole stimulates dopamine receptors directly and thus bypasses the increasingly depleted dopaminergic neurons. Pramipexole has a more favourable long-term motor profile, but a higher risk of neuropsychiatric side effects such as impulse control disorders. Both are often combined.

Can pramipexole be taken long-term for restless legs syndrome?

Pramipexole can be used long-term for RLS; however, after several years there is a risk of augmentation. Regular follow-up checks and, if necessary, a change of therapy (e.g. to alpha-2-delta ligands such as pregabalin) are important with long-term therapy.

What to do with unusual behavioural changes under pramipexole?

Impulse control disorders such as gambling addiction or increased sexual drive must be discussed immediately with the treating physician. In most cases, these symptoms improve after dose reduction or change of therapy.

References

• Product information Mirapex (Boehringer Ingelheim), as of 2024
• S3 guideline Idiopathic Parkinson's Syndrome of the German Society for Neurology (DGN), 2023
• European Medicines Agency (EMA): Mirapex EPAR
• Winkelman JW et al.: Practice guideline summary: Treatment of restless legs syndrome in adults. Neurology, 2016
• Federal Institute for Drugs and Medical Devices (BfArM): Product monograph Pramipexole